Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer. Issue 20 (12th May 2021)

• Record Type: Journal Article
• Authors: Lesniak, Wojciech G.; Wu, Yixuan; Kang, Jeeun; Boinapally, Srikanth; Ray Banerjee, Sangeeta; Lisok, Ala; Jablonska, Anna; Boctor, Emad M.; Pomper, Martin G.
• Is Part Of: Nanoscale. Volume 13:Issue 20(2021)
• Page Start: 9217
• Page End: 9228
• Publication Date: 2021-05-12
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/d1nr00669j
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : PAMAM dendrimers can serve as scaffolds for dual contrast imaging in vivo . Here they target tumors expressing the prostate-specific membrane antigen (PSMA) for fluorescence and photoacoustic imaging. Abstract : Prostate-specific membrane antigen (PSMA) is a promising diagnostic and therapeutic target for prostate cancer (PC). Poly(amidoamine) [PAMAM] dendrimers serve as versatile scaffolds for imaging agents and drug delivery that can be tailored to different sizes and compositions depending upon the application. We have developed PSMA-targeted PAMAM dendrimers for real-time detection of PC using fluorescence (FL) and photoacoustic (PA) imaging. A generation-4, ethylenediamine core, amine-terminated dendrimer was consecutively conjugated with on average 10 lysine-glutamate-urea PSMA targeting moieties and a different number of sulfo-cyanine7.5 (Cy7.5) near-infrared dyes (2, 4, 6 and 8 denoted as conjugates II, III, IV and V, respectively). The remaining terminal primary amines were capped with butane-1, 2-diol functionalities. We also prepared a conjugate composed of Cy7.5-lysine-suberic acid-lysine glutamate-urea (I) and control dendrimer conjugate (VI). Among all conjugates, IV showed superior in vivo target specificity in male NOD-SCID mice bearing isogenic PSMA + PC3 PIP and PSMA − PC3 flu xenografts and suitable physicochemical properties for FL and PA imaging. Such agents may prove useful in PC cancer detection and subsequent surgical guidance during excision of PSMA-expressing lesions.